Global Lyme Disease Market, By Disease Type (Lyme Carditis, Lyme Arthritis, Neurologic Lyme Disease , Borrelial Lymphocytosis and Post-treatment Lyme Disease Syndrome), Stages Type (Localized Early Stage, Disseminated Stage and Late Stage), Treatment Type (Medication and Tick removal), Diagnosis Type (Blood Test, Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immuno fluorescent Staining, Nucleic acid Test and Enzyme-linked Immuno sorbent Assay (ELISA) Test), Drug Type (Doxycycline, Cefuroxime axetil, Amoxicillin, Ceftriaxone and Others), Route of Administration (Oral, Topical and Intravenous), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Lyme Disease Drug Market
Rising prevalence of lyme disease and rising demand for novel therapies are attributable to the growth of lyme disease market value. Data Bridge Market Research analyses that the lyme disease will exhibit a CAGR of around 6.4% for the forecast period of 2021-2028.
Lyme disease is a tick-borne illness caused by bacteria called Borrelia burgdorferi. Lyme disease is transmitted to humans through a bite of an infected black legged tick. The infection spreads through the blood stream causing wide range of symptoms depending upon the stages. Lyme disease is a contagious disease that shows common indications or symptoms like redness, fatigue, skin rashes and other flu-like symptoms.
Rising prevalence of lyme disease is a key factor influencing the growth of the market. Growth in the number of tick borne diseases and vector borne diseases are fostering the growth of lyme disease market value. Widespread of domestic pet lovers is indirectly inducing the growth of lyme disease market.
However, lack of awareness about the disease in underdeveloped economies will derail the market growth rate. Underdeveloped healthcare infrastructure in these regions is another factor demoting the market growth rate. High costs associated with the treatment will further restrict the scope of growth.
This lyme disease market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lyme disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lyme Disease Market Scope and Market Size
The lyme disease market is segmented on the basis of disease type, stages type, treatment type, diagnosis type, drug type, route of administration and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on the disease type, the lyme disease market has been segmented into lyme carditis, lyme arthritis, neurologic lyme disease, borrelial lymphocytosis and post-treatment lyme disease syndrome.
- On the basis of stages type, the lyme disease market is segmented into localized early stage, disseminated stage and late stage.
- On the basis of treatment type, the market is segmented into medication and tick removal.
- On the basis of diagnosis type, the market is segmented into blood test, serological test, urine antigen tests, lymphocytic transformation test, immuno fluorescent staining, nucleic acid test and enzyme-linked immuno sorbent assay (ELISA) Test.
- On the basis of drug type, the market is segmented into doxycycline, cefuroxime axetil, amoxicillin, ceftriaxone and others.
- On the basis of route of administration, the lyme disease market is segmented into oral, tropical and intravenous.
- On the basis of end users, the lyme disease market is segmented into hospitals, homecare, specialty clinics and others.
Lyme Disease Market Country Level Analysis
The lyme disease market is analysed and market size insights and trends are provided by country, disease type, stages type, treatment type, diagnosis type, drug type, route of administration and end users as referenced above.
The countries covered in the lyme disease market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the lyme disease market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies and rapid adoption of new and better healthcare technologies. Rising prevalence of lyme disease is inducing the dominance of the region as well. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure, rising domestic pet lovers and rising awareness about the illness.
The country section of the lyme disease market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Lyme disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of lyme disease market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Lyme Disease Market Share Analysis
The lyme disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to lyme disease market.
The major players covered in the lyme disease market report are Mylan N.V, GlaxoSmithKline plc., Pfizer Inc., Abbott, Eli Lilly And Company., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Valneva SE., Bio-Rad Laboratories, Inc., T2 Biosystems, Inc., Canon U.S.A., Inc., G&W Laboratories, Inc. and BioDiem among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
